4D Molecular Therapeutics Presents Two-Year 4D-150 Data Showing Reduced Injection Burden in Wet AMD
Bitget2026/10/21 16:21- 4D Molecular Therapeutics presented stable two-year vision and retinal anatomy results for wet AMD therapy 4D-150 in New York City.
- The broad PRISM Phase 2b population showed a 78% reduction in injections versus projected treatment needs; 46% remained injection-free.
- Recently diagnosed patients achieved an 87% reduction in injections versus projected treatment needs; 66% remained injection-free over two years.
- The 4FRONT Phase 3 program targets treatment-naive, recently diagnosed wet AMD patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Turtle Creek Asset Management Reports Sale of $347,850 in Jeld-Wen Common Shares
GLOBALFOUNDRIES Director Ganesh Moorthy Reports $93,687.50 Share Acquisition
Crypto prices
More
